Assessing the Therapeutic and Toxicological Profile of Novel Acetylcholinesterase Reactivators: Value of In Silico And In Vitro Data
Jazyk angličtina Země Spojené arabské emiráty Médium print
Typ dokumentu přehledy, časopisecké články
PubMed
36239718
DOI
10.2174/0929867330999221014104610
PII: CMC-EPUB-126970
Knihovny.cz E-zdroje
- Klíčová slova
- Reactivators, acetylcholinesterase, computational methods, drug development, military toxicology, organophosphorus compounds,
- MeSH
- acetylcholinesterasa chemie MeSH
- antidota * farmakologie terapeutické užití chemie MeSH
- cholinesterasové inhibitory toxicita MeSH
- organofosforové sloučeniny MeSH
- oximy terapeutické užití toxicita MeSH
- reaktivátory cholinesterasy * terapeutické užití toxicita MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- acetylcholinesterasa MeSH
- antidota * MeSH
- cholinesterasové inhibitory MeSH
- organofosforové sloučeniny MeSH
- oximy MeSH
- reaktivátory cholinesterasy * MeSH
Organophosphorus compounds (OP) make up an important class of inhibitors, mostly employed as pesticides, even as chemical weapons. These toxic substances act through the inhibition of the acetylcholinesterase (AChE) enzyme, which results in elevated synaptic acetylcholine (ACh) levels, leading to serious adverse effects under the cholinergic syndrome. Many reactivators have been developed to combat the toxic effects of these AChE inhibitors. In this line, the oximes highlight because of their good reactivating power of cholinesterase enzymes. To date, no universal antidotes can reactivate AChE inhibited by any OP agent. This review summarizes the intoxication process by neurotoxic OP agents, along with the development of reactivators capable of reversing their effects, approaching aspects like the therapeutic and toxicological profile of these antidotes. Computational methods and conscious in vitro studies, capable of significantly predicting the toxicological profile of these drug candidates, might support the process of development of these reactivators before entering in vivo studies in animals, and then clinical trials. These approaches can assist in the design of safer and more effective molecules, reducing related cost and time for the process.
Department of Chemistry Federal University of Lavras Lavras Brazil
Institute of Physics and Chemistry Federal University of Itajuba Itajuba Brazil
Citace poskytuje Crossref.org
Molecular Modeling Insights on the Pharmaceuticals and Hypotheses of Alzheimer's Disease